TORONTO, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Scythian Biosciences Corp. (the "Company" or
“Scythian”) (TSX-V:SCYB) (Frankfurt:9SB) (OTC Pink:SCCYF) announces that its Board of Directors has approved a
proposed up to eight (8) for one (1) stock split of its outstanding common shares. The stock split is subject to the approval of
the TSX Venture Exchange and the approval of Scythian’s shareholders at Scythian’s Special Meeting of Shareholders. Scythian has
approximately 5.43 million common shares currently outstanding, and after giving effect to the maximum proposed eight (8) for one
(1) stock split, Scythian will have approximately 43.4 million common shares outstanding.
About Scythian Biosciences Corp.
Scythian is a research and development company committed to finding a solution for the prevention and treatment
of concussions and traumatic brain injury with its proprietary Cannabinoid combination.
Scythian’s mission is to be the first accepted drug regimen for concussive treatment. Scythian has recently
formed a collaboration with the University of Miami and its world renowned neuroscientific team to conduct pre-clinical and
clinical trials of its drug regimen. The University of Miami believes that Scythian’s scientific approach shows significant
promise and differs from previous approaches to treat this growing problem. The collaboration with the University of Miami
allows access to their extensive knowledge base in the fields of traumatic brain injury and concussions and allows for Scythian’s
clinical studies to be undertaken at their world-class facilities.
Gillian A. Hotz, PhD, is leading Scythian’s program at the University of Miami. Dr. Hotz is a nationally
recognized behavioral neuroscientist and expert in neurotrauma, concussion management, and neurorehabilitation. She has
extensive experience in neurocognitive testing. Dr. Hotz has been the co-director of University of Miami Miller School of
Medicine’s Concussion Program since 1995.
Scythian is also endorsed by Pro Football Legends and the World Boxing Association on its mission.
Contact Information
For further information, please contact:
Scythian Biosciences Corp.
Jonathan Gilbert, CEO
Phone: (212) 729-9208
Email: info@scythianbio.com
Cautionary Statements
This press release may contain certain forward-looking information and statements
(“forward-looking information”) within the meaning of applicable Canadian securities legislation,
that are not based on historical fact, including without limitation statements containing the words "believes", "anticipates",
"plans", "intends", "will", "should", "expects", "continue", "estimate", "forecasts" and other similar expressions.
Readers are cautioned to not place undue reliance on forward-looking information. Actual results and developments may
differ materially from those contemplated by these statements. The Company undertakes no obligation to comment on
analyses, expectations or statements made by third-parties in respect of the Company, its securities, or financial or
operating results (as applicable). Although the Company believes that the expectations reflected in forward-looking
information in this press release are reasonable, such forward-looking information has been based on expectations, factors and
assumptions concerning future events which may prove to be inaccurate and are subject to numerous risks and uncertainties, certain
of which are beyond the Company’s control, including the risk factors discussed in the Filing Statement which are incorporated
herein by reference and are available through SEDAR at www.sedar.com. The forward-looking information contained
in this press release are expressly qualified by this cautionary statement and are made as of the date hereof. The Company
disclaims any intention and has no obligation or responsibility, except as required by law, to update or revise any forward-looking
information, whether as a result of new information, future events or otherwise.
NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE
POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.
